Stealth BioTherapeutics Corp. (MITO)
| Market Cap | 14.05M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -52.53M |
| Shares Out | 59.97M |
| EPS (ttm) | -0.92 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 686,169 |
| Open | 0.248 |
| Previous Close | 0.245 |
| Day's Range | 0.227 - 0.265 |
| 52-Week Range | 0.175 - 2.100 |
| Beta | 1.88 |
| Analysts | Buy |
| Price Target | 2.41 (+929.0%) |
| Earnings Date | May 17, 2022 |
About MITO
Stealth BioTherapeutics Corp, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies for diseases involving mitochondrial dysfunction. Its lead product candidate is Elamipretide that is in phase 3 clinical trial to treat barth syndrome, phase 2/3 clinical trial for the treatment of duchenne cardiomyopathy, phase 2a clinical trial to treat friedreich's ataxia, phase 2 clinical trial for the treatment of dry age-related macular degeneration, phase 2 clinical trial to treat leber's heredit...
Financial Performance
Financial StatementsAnalyst Forecast
According to 8 analysts, the average rating for MITO stock is "Buy." The 12-month stock price forecast is 2.41, which is an increase of 929.04% from the latest price.
News
Stealth BioTherapeutics Receives Orphan Drug Designation from FDA for Elamipretide for Treatment of Duchenne Muscular...
Pre-IND meeting request granted by FDA's Division of Neurology I BOSTON , May 12, 2022 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the ...
What to Know About Buying Penny Stocks on May 10th
Here's what you need to know about trading penny stocks today The post What to Know About Buying Penny Stocks on May 10th appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks...
Stealth Bio Posts Disappointing Elamipretide Data From Mid-Stage Geographic Atrophy Study
Stealth BioTherapeutics Corp (NASDAQ: MITO) has announced topline data from its Phase 2 ReCLAIM-2 trial evaluating elamipretide in geographic atrophy (GA) secondary to dry age-related macular degenerati...
STEALTH BIOTHERAPEUTICS ANNOUNCES DATA FROM RECLAIM-2 PHASE 2 TRIAL OF ELAMIPRETIDE IN GEOGRAPHIC ATROPHY
Study did not meet primary endpoints of mean change in low luminance visual acuity (LLVA) and geographic atrophy (GA) progression Categorical improvement in LLVA, with >15% of elamipretide-treated patie...
Stealth BioTherapeutics Announces $8.5 Million in Equity Financings
BOSTON , April 11, 2022 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO) (the "Company"), a clinical-stage biotechnology company focused on the discovery, development and commercialization of...
Stealth BioTherapeutics Announces New SBT-272 Data and Trial Initiation
BOSTON , March 30, 2022 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapie...
Stealth BioTherapeutics Receives Orphan Drug Designation from FDA for Elamipretide for the Treatment of Friedreich's ...
Phase 2a clinical trial in Friedreich's ataxia has been initiated and is currently recruiting patients BOSTON , March 28, 2022 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq:MITO), a clinical-stag...
Stealth BioTherapeutics Announces New Data on Complement Gene Expression and Cell Survival in Dry AMD to be Presented...
BOSTON , March 24, 2022 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapie...
Stealth BioTherapeutics to Host Virtual Event on the Potential of Elamipretide in Treatment of Geographic Atrophy in ...
BOSTON , March 17, 2022 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq:MITO), a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies...
Stealth BioTherapeutics Showcases New Duchenne Muscular Dystrophy Nonclinical Data at the 2022 Muscular Dystrophy Ass...
BOSTON, March 16, 2022 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq:MITO), a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies ...
Stealth BioTherapeutics to Present at Upcoming March Investor Conferences
BOSTON , March 9, 2022 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq:MITO), a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies ...
Stealth BioTherapeutics to Present at Mitochondria-Targeted Drug Development Summit
BOSTON, Feb. 22, 2022 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq:MITO), a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies f...
Last Patient Completes Treatment in Stealth BioTherapeutics' Phase 2 Geographic Atrophy Clinical Trial
BOSTON, Feb. 15, 2022 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq:MITO), a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies f...
Stealth BioTherapeutics Receives Nasdaq Notification Regarding Minimum Market Value Of Publicly Held Shares Requirement
BOSTON , Feb. 11, 2022 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq:MITO), a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies ...
Stealth BioTherapeutics Announces Oral Presentation of New Duchenne Muscular Dystrophy Data at the 2022 Muscular Dyst...
BOSTON, Feb. 8, 2022 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies f...
Stealth BioTherapetuics Receives Nasdaq Notifications Regarding Minimum Bid And Market Value Requirements
BOSTON, Jan. 7, 2022 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq:MITO), a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies fo...
Stealth BioTherapeutics to Present at 2022 H.C. Wainwright BioConnect Virtual Conference
BOSTON, Jan. 4, 2022 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies f...
Stealth BioTherapeutics Reports Positive Pre-IND Meeting for Duchenne Muscular Dystrophy
BOSTON, Dec. 20, 2021 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq:MITO), a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies f...
Stealth BioTherapeutics Provides Update On Clinical Stage Rare Disease Programs
BOSTON, Dec. 13, 2021 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq:MITO), a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies f...
Stealth BioTherapeutics Reports Third Quarter 2021 Financial Results and Recent Business Highlights
BOSTON, Nov. 11, 2021 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq:MITO), a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies f...
Stealth BioTherapeutics to Report Third Quarter Financial Results on Thursday, November 11
BOSTON, Nov. 4, 2021 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies fo...
Stealth Bio Stock Falls On FDA Refusal to File Letter For Barth Syndrome Candidate
Stealth BioTherapeutics Corp (NASDAQ: MITO) has received a Refusal to File letter from the FDA regarding its marketing application for elamipretide, a mitochondria-targeted therapy for Barth syndrome. B...
Stealth BioTherapeutics Receives Refusal to File Letter from the FDA
BOSTON, Oct. 20, 2021 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies ...
Stealth BioTherapeutics Presents Positive SBT-272 Preclinical Data at 2021 Annual Northeast Amyotrophic Lateral Scler...
BOSTON, Oct. 7, 2021 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies fo...
Stealth BioTherapeutics Completes a $25 Million Debt Financing with Horizon Technology Finance
BOSTON, Oct. 4, 2021 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies f...